Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Benign Prostatic Hypertrophy Implant Devices Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 January 11
SKU : MD3678
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Benign Prostatic Hypertrophy Implant Devices Market is segmented By Product Type (Prostatic Urethral Lift, Transurethral Resection of the Prostate (TURP), Prostatectomy, Laser Surgery, Transurethral Microwave Therapy (TUMT), Others), By End-User (Hospitals, Ambulatory Surgery Centers), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

The Benign Prostatic Hypertrophy Implant Devices Market is estimated to reach at a high CAGR 6.7% during the forecast period 2022-2029.

Benign prostatic hyperplasia (BPH) is also called prostate gland enlargement, which is a common condition as men get older. 

The prostatic urethral lift procedure, more commonly known as UroLift, has been designed to improve male lower urinary tract symptoms while avoiding the complications and disadvantages of existing drug and surgical therapies. The device compresses the tissue and delivers tiny implants to lift and hold prostate tissue out of the way, thus opening the urethra.

Benign Prostatic Hypertrophy Implant Devices Market



Market CAGR


Segments Covered

By Product Type, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Market Dynamics

Increasing incidences of benign prostatic hyperplasia (BPH) will drive market growth. And increasing demand for minimally invasive therapies is expected to boost the growth of the Benign Prostatic Hypertrophy Implant Devices Market

Increasing incidences of benign prostatic hyperplasia (BPH) will drive the market growth

Benign prostatic hyperplasia (BPH), is also known as benign prostatic hypertrophy. It is a histologic diagnosis characterized by the proliferation of the cellular elements of the prostate, leading to an enlarged prostate gland. 

BPH is seen in up to 90% of men by age 85 years. Around 14 million men in the United States have symptoms of BPH. Worldwide, approximately 30 million men have symptoms related to BPH. BPH symptoms are gnereally obstruction of  the flow of urine through the urethra. BPH related symptoms are present in about one in four men by age 55 and half of 75-year-old men. By age 80, around 20% to 30% of men experience BPH symptoms severe enough that may require treatment. Until the recent approval of minimally invasive procedures that open the prostatic urethra surgery was the only option  and drugs that can relieve symptoms by shrinking the prostate or relaxing the prostate muscle tissue that constricts the urethra.

There are different variety of treatments available for enlarged prostate, including medication, minimally invasive therapies, and surgery. Treatments focus on prostate growth, which is the cause of BPH symptoms. Once prostate growth starts, it often continues unless medical therapy is started.

Increasing demand for minimally invasive therapies will drive the market in the forecast period

Researchers have developed several minimally invasive procedures that relieve benign prostatic hyperplasia symptoms when medications prove ineffective. The surgery offers patients several benefits such as smaller incisions, faster recovery times, reduced pain, and scarring. In many cases, minimally invasive surgery also provides a higher accuracy rate compared to traditional open surgery. The procedures generally include transurethral needle ablation, transurethral microwave thermotherapy, high-intensity focused ultrasound, transurethral electrovaporization, water-induced thermotherapy, prostatic stent insertion. Minimally invasive procedures help to destroy enlarged prostate tissue or widen the urethra, which may relieve the blockage and urinary retention caused by benign prostatic hyperplasia.

The transurethral method, involving insertion of catheter a thin, flexible tube or cystoscope through the urethra to reach the prostate is used by  urologists to  perform minimally invasive procedures .They require local, regional, or general anesthesia.

The side effects suffered by patients after benign prostatic hyperplasia (BPH) will hamper the market

The symptoms of BPH are easy to ignore. However, early treatment can help one to avoid potentially dangerous complications. People with a long  history of BPH may have  the following complications: urinary tract infections, urinary stones, kidney damage, bleeding in the urinary tract, and a sudden inability to urinate

Urinary obstruction from BPH is so severe sometimes  that no urine can leave the bladder at all. This is called bladder outlet obstruction. This can be dangerous because urine trapped in the bladder can cause urinary tract infections and damage the kidneys. Prostate procedures can cause side effects. Depending on the procedure  choosen, complications might include semen flowing backward into the bladder instead of out through the penis during ejaculation (retrograde ejaculation), difficulty with urination which can be temporarily , urinary tract infection, bleeding, erectile dysfunction, and very rarely, loss of bladder control (incontinence).

Benign Prostatic Hypertrophy Implant Devices Market Industry Analysis.

COVID-19 Impact Analysis

COVID-19 has severely impacted the supply and demand of resources. There is inadequate production of nephrology and urology devices due to restrictions imposed by the government. All factories and manufacturing services have been shut down. This will impact the Benign Prostatic Hypertrophy Implant Devices Market

Segment Analysis

The prostatic urethral lift will dominate the market in the forecast period

A prostatic urethral lift (PUL) is a medical procedure that helps to  relieve the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate. In this procedure, the urologist inserts an instrument into the urethra and moves it forward. When the device reaches the prostate's lateral (side) wall, it ejects  a small, thin implants into both the sides of the prostate, pulling the urethra , prostate to open the channel.

Based  on the size of the prostate, the urologist will place  2 to 6 implants. Separating the lobes of the prostate in this manner, to  creates an easier pathway for urination and helps relieve the symptoms of BPH. PUL (Urolift, NeoTract, Pleasanton, CA, USA) compresses the obstructing lateral lobes using a  small permanent suture-based tissue-retracting implants loaded on to a dedicated delivery device. The implants are placed anterolaterally at 2 o'clock and 10 o'clock positions under cystoscopic control which  results in the creation of a continuous anterior channel through the prostatic lumen extending from the bladder neck to the verumontanum.

Teleflex Incorporated announced the U.S. Food and Drug Administration (FDA) had granted the company an expanded indication for using its UroLift System to treat larger prostates, between 80cc and100cc. This minimally invasive, in-office treatment provides rapid relief and recovery from the symptoms of benign prostatic hyperplasia (BPH).

Hospitals dominated the benign prostatic hypertrophy implant devices market

BPH requires often active surveillance. If the patient and the  doctor choose this treatment option, then BPH will be closely watched but not actively treated. Which means that BPH is monitored with regular visits to a urologist. A yearly exam is common. A  health care provider will look for worse and new issues before suggesting anything else. Diet and exercise are often recommended as a way to prevent or manage  symptoms.

For men with mild to moderate symptoms active surveillance is best. It is also an option for men who are not bothered by the effects of BPH. If  symptoms worsen, or if new symptoms appear, the doctor may suggest to begin active treatment. To remove only the enlarged tissue pressing against the urethra (the tube that carries urine out of the body), the rest of the inside prostate left intact surgery might be needed. Hospitals and clinics will have the best advanced technologies.

Geographical Analysis

North America will dominate the market in the forecast period

The high incidence rate of the geriatric population in this region and advancements in the healthcare technology in this region will drive benign prostatic hypertrophy implant devices market growth.

Of the 270 million people in the United States, about 13 percent are aged 65 years or older. As in most other countries worldwide, this proportion of the population is projected to increase in the coming years. In 2019, around 16.5 percent of the American population was 65 years old or over, expected to reach 22 percent by 2050.

In the United States alone BPH condition affects over 40 million men , with men more than 40 percent of over 50 years of age and 80 percent of men over 70 years having BPH.

Urotronic Inc.,is  a medical device company pioneering a new solution that could dramatically change the way millions of men worldwide with enlarged prostates are treated, has received U.S. Food and Drug Administration (FDA) approval to begin its U.S. pivotal study Optilume BPH Catheter System.  
More than 12 million American men are reported to suffer from Benign Prostatic Hyperplasia (BPH) or enlarged prostates. And over 750,000 new cases are diagnosed each year.

Competitive Landscape

Some prominent key players in this market are Olympus Corporation, Boston Scientific Corporation, Medifocus Inc., KARL STORZ SE & Co. KG, NxThera, Inc., ProArc Medical, Lisa Laser Products OHG,  Richard Wolf Gmbh, Guangzhou Maya Medical and Guangzhou Medunion Technologies

Benign Prostatic Hypertrophy Implant Devices Market Key Companies to Watch

Olympus Corporation

Overview: Olympus Corporation is a Japanese manufacturer of optics and reprography products. It was established on 12 October 1919, initially specializing in microscopes and thermometers. Olympus believes to put much good back into the world, and what they do matters.They  are committed to making people's lives healthier, safer and more fulfilling every day by crafting innovative optical and digital solutions in medical technologies, life sciences, industrial solutions, and cameras and audio products. Everything they do at Olympus reflects their vision, and everyone helps to make it a reality. They view their relationship and commitment to  employees with the same passion. Everything they do at Olympus reflects their purpose and everyone  helps to make it a reality. They invest in their employees, great ideas, and how they impact the communities around us. Through multiple lenses, they  see the world and come together to find the right answers, the best solutions.

Product Portfolio: Olympus Corporation is the manufacturer of optics and reprography products. They craft innovative optical and digital solutions in medical technologies.

Key Development: On April 6, 2020, Olympus, a global technology leader in designing and delivering innovative solutions for medical, surgical procedures  announced the FDA de Novo classification of the iTind device,which is  a non-surgical device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH). The iTind device was developed by the Israeli-based medical device manufacturer Medi-Tate. Through investment in Medi-Tate, Olympus holds the exclusive right to distribute Medi-Tate products, including the iTind device, in the U.S.

The Benign Prostatic Hypertrophy Implant Devices Market report would provide an access to an approx. 52 market data table, 43  figures and 200 pages. 

Trending Topics

Benign Prostate Hyperplasia (BPH) Market

Metastatic Prostate Cancer Treatment Market

Prostate Specific Antigen Testing Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version